Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT00748163 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Study has been abandoned for lack of available funding.

Conditions

Interventions

Sponsor

Masonic Cancer Center, University of Minnesota